Leukemia — Expanded Access Programs
Overview
Right2Hope maintains a directory of 31 expanded access programs, clinical trials, and compassionate use pathways listed for Leukemia. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with leukemia programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 20 programs are currently active or recruiting, with the remaining 11 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Children's Hospital of Philadelphia, Daiichi Sankyo, Dana-Farber Cancer Institute, and others.
By recruiting status
Snapshot of where every Leukemia program currently sits in its lifecycle.
- Active / Recruiting20
- Inactive11
Top sponsors
Organisations running the most Leukemia programs in the directory.
- M.D. Anderson Cancer Center7 programs
- Memorial Sloan Kettering Cancer Center7 programs
- Children's Hospital of Philadelphia2 programs
- Daiichi Sankyo2 programs
- Dana-Farber Cancer Institute2 programs
- City of Hope Medical Center1 program
- H. Lee Moffitt Cancer Center and Research Institute1 program
- Hannah Choe, MD1 program
- Inhye Ahn1 program
- Jacqueline Garcia, MD1 program
Leukemia programs (31)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Multi-Site Cancer Trial: Targeting Residual Disease in Acute Myeloid Leukemia with Tagraxofusp, Azacitidine, and Venetoclax — Jacqueline Garcia, MD
- Study on a New Treatment Plan for Adults Aged 18-60 with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia — Memorial Sloan Kettering Cancer Center
- Phase II Study of Ibrutinib Plus FCR for Untreated Younger Patients with Chronic Lymphocytic Leukemia — Dana-Farber Cancer Institute
- Phase II Study of Vemurafenib and Obinutuzumab for Untreated Classical Hairy Cell Leukemia — Memorial Sloan Kettering Cancer Center
- Study on CPI-613 for Patients with Difficult or Returning Burkitt Lymphoma/Leukemia or High-Risk B-Cell Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on Revumenib and Mezigdomide for Treating Leukemia — Memorial Sloan Kettering Cancer Center
- Study on Adding Capivasertib to Chemotherapy and Venetoclax for Adults with ALL/LBL — University of Chicago
- Study on Lenalidomide and Rituximab Combination for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) — M.D. Anderson Cancer Center
- Cord Blood Transplantation for Children and Young Adults with Blood Cancer — Memorial Sloan Kettering Cancer Center
- Study on Low Dose Cyclophosphamide, Tacrolimus, and Ruxolitinib for Preventing Graft-versus-Host Disease in Stem Cell Transplant Patients — Hannah Choe, MD
- Study on Two Different Doses of Quizartinib for Maintenance in Acute Myeloid Leukemia Patients in Complete Remission — Daiichi Sankyo
- Expanded Access Program for Stem Cell Transplant Using Special Donor Cells — Children's Hospital of Philadelphia
- Study on Helical Tomotherapy, Fludarabine, and Melphalan Followed by Donor Stem Cell Transplant for Blood Cancers — City of Hope Medical Center
- Study on Mosunetuzumab for Clearing Minimal Residual Disease in Chronic Lymphocytic Leukemia (CLL) — Inhye Ahn
- Study on Nivolumab and/or Ipilimumab With or Without Azacitidine for Treating Myelodysplastic Syndrome — M.D. Anderson Cancer Center
- Study on Quizartinib or Placebo with Chemotherapy for Newly Diagnosed Patients with FLT3-ITD Negative Acute Myeloid Leukemia (AML) — Daiichi Sankyo
- Study on Roginolisib, Venetoclax, and Rituximab for Treating Difficult or Returning Chronic Lymphocytic Leukemia (CLL) — Jennifer R. Brown, MD, PhD
- Study on Ruxolitinib for Treating Chronic Myelomonocytic Leukemia (CMML): Phase 2 Expansion — H. Lee Moffitt Cancer Center and Research Institute
- Study on the Safety and Dosage of Neratinib for Children and Young Adults with Cancer That Has Returned or Not Responded to Treatment — Memorial Sloan Kettering Cancer Center
- Study on Using Genetically Modified T Cells to Treat Relapsed or Resistant Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma — Memorial Sloan Kettering Cancer Center
- Study on Genetically Modified T Cells Targeting CD22 for Children and Young Adults with Difficult-to-Treat Leukemia or Lymphoma — Seattle Children's Hospital
- Phase II Study of Ponatinib with Mini-hyper CVD Chemotherapy and Venetoclax for Patients with Relapsed or Hard-to-Treat T-cell Acute Lymphoblastic Leukemia — M.D. Anderson Cancer Center
- Phase II Study of Revumenib for Leukemia with Increased HOX Gene Activity — M.D. Anderson Cancer Center
- A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia — Takeda
- Study on Using Donor Stem Cell Transplant with T and B Cell Depletion for Blood Cancers — Children's Hospital of Philadelphia
- Study on CD30biAb-AATC for Treating CD30+ Cancers — Medical College of Wisconsin
- Study on Cladribine Plus Low Dose Cytarabine and Decitabine for Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) — M.D. Anderson Cancer Center
- Study on Enasidenib for Treating Anemia in Patients with Lower Risk Myelodysplastic Syndrome or Non-Proliferative Chronic Myelomonocytic Leukemia Without IDH2 Mutation — Stanford University
- Study on Mini-Hyper-CVD with Rituximab, Inotuzumab Ozogamicin, and Blinatumomab for Relapsed B-Cell Acute Lymphocytic Leukemia in Children — M.D. Anderson Cancer Center
- Study on a New Combination Treatment for Patients with Untreated Chronic Lymphocytic Leukemia or Richter Transformation — M.D. Anderson Cancer Center
- Venetoclax and Chemotherapy as Initial Treatment for Older Patients and Those with Relapsed or Hard-to-Treat Acute Lymphoblastic Leukemia (ALL) — Dana-Farber Cancer Institute
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Leukemia to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.